 |
|
 |
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts
Divisions of Infectious Diseases
¶ General Pediatrics, Children's Hospital Boston, Boston, Massachusetts
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia
|| Massachusetts Department of Public Health, Boston, Massachusetts
Background. The incidence of reported pertussis among adolescents, adults, and young infants has increased sharply over the past decade. Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany and may soon be considered for use in the United States.
Objective. To evaluate the potential health benefits, risks, and costs of a national pertussis vaccination program for adolescents and/or adults.
Design, Setting, and Population. The projected health states and immunity levels associated with pertussis disease and vaccination were simulated with a Markov model. The following strategies were examined from the health care payer and societal perspectives: (1) no vaccination; (2) 1-time adolescent vaccination; (3) 1-time adult vaccination; (4) adult vaccination with boosters; (5) adolescent and adult vaccination with boosters; and (6) postpartum vaccination. Data on disease incidence, costs, outcomes, vaccine efficacy, and adverse events were based on published studies, recent unpublished clinical trials, and expert panel input.
Main Outcome Measures. Cases prevented, adverse events, costs (in 2004 US dollars), cost per case prevented, and cost per quality-adjusted life-year (QALY) saved.
Results. One-time adolescent vaccination would prevent 30800 cases of pertussis (36% of projected cases) and would result in 91000 vaccine adverse events (67% local reactions). If pertussis vaccination cost $15 and vaccine coverage was 76%, then 1-time adolescent vaccination would cost $1100 per case prevented (or $1200 per case prevented) or $20000 per QALY (or $23000 per QALY) saved, from the societal (or health care payer) perspective. With a threshold of $50000 per QALY saved, the adolescent and adult vaccination with boosters strategy became potentially cost-effective from the societal perspective only if 2 conditions were met simultaneously, ie, (1) the disease incidence for adolescents and adults was 
6 times higher than base-case assumptions and (2) the cost of vaccination was less than $10. Adult vaccination strategies were more costly and less effective than adolescent vaccination strategies. The results were sensitive to assumptions about disease incidence, vaccine efficacy, frequency of vaccine adverse events, and vaccine costs.
Conclusions. Routine pertussis vaccination of adolescents results in net health benefits and may be relatively cost-effective.
Key Words: pertussis • cost-effectiveness • adolescent • immunization • vaccine
Abbreviations: QALY, quality-adjusted life-year • CE, cost-effectiveness • Td, tetanus-diphtheria • TdaP, tetanus-diphtheria-acellular pertussis • LYS, life-year saved
This article has been cited by other articles:
 |
|
 |
|
  A. M. Dylag and S. I. Shah Administration of Tetanus, Diphtheria, and Acellular Pertussis Vaccine to Parents of High-Risk Infants in the Neonatal Intensive Care Unit Pediatrics, September 1, 2008; 122(3): e550 - e555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sotir, D. L. Cappozzo, D. M. Warshauer, C. E. Schmidt, T. A. Monson, J. L. Berg, J. A. Zastrow, G. W. Gabor, and J. P. Davis A Countywide Outbreak of Pertussis: Initial Transmission in a High School Weight Room With Subsequent Substantial Impact on Adolescents and Adults Arch Pediatr Adolesc Med, January 1, 2008; 162(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Ortega-Sanchez, G. M. Lee, R. J. Jacobs, L. A. Prosser, N.-A. Molinari, X. Zhang, W. B. Baine, M. M. McCauley, T. Miller, and for the Working Group on Leading Economic Issues f Projected Cost-effectiveness of New Vaccines for Adolescents in the United States Pediatrics, January 1, 2008; 121(Supplement_1): S63 - S78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Benbassat and R. Baumal The time horizons of formal decision analyses QJM, June 1, 2007; 100(6): 383 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rein, K. A. Hicks, K. E. Wirth, K. Billah, L. Finelli, A. E. Fiore, T. J. Hoerger, B. P. Bell, and G. L. Armstrong Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States Pediatrics, January 1, 2007; 119(1): e12 - e21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pichichero, M. M. Blatter, W. A. Kennedy, J. Hedrick, D. Descamps, and L. R. Friedland Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents Pediatrics, April 1, 2006; 117(4): 1084 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Committee on Infectious Diseases Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Pediatrics, March 1, 2006; 117(3): 965 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Caro, G. Denis, L. Coudeville, and A. Van Rie Pertussis in Adolescents and Adults: Should We Accept the Results? Pediatrics, November 1, 2005; 116(5): 1263 - 1263. [Full Text] [PDF]
|
|
|
|
|
|
G. Lee, T. Lieu, C. LeBaron, T. Murphy, S. Lett, and S. Schauer Pertussis in Adolescents and Adults: Should We Accept the Results?: In Reply Pediatrics, November 1, 2005; 116(5): 1263 - 1264. [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Davis Varicella Vaccine, Cost-effectiveness Analyses, and Vaccination Policy JAMA, August 17, 2005; 294(7): 845 - 846. [Full Text] [PDF]
|
|
 |
||
|
||
Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 2005 American Academy of Pediatrics. All rights reserved. |
||
|
||
